Oripavine
| Names | |
|---|---|
| IUPAC name
6,7,8,14-Tetradehydro-4,5α-epoxy-6-methoxy-17-methylmorphinan-3-ol
| |
| Other names
3-O-desmethylthebaine
| |
| Identifiers | |
CAS Number
|
|
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.006.715 |
| EC Number |
|
| KEGG | |
| MeSH | Oripavine |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
InChI
| |
SMILES
| |
| Properties | |
Chemical formula
|
C18H19NO3 |
| Molar mass | 297.348 g/mol |
| Pharmacology | |
| N02A (WHO) | |
| SC | |
| Legal status |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
| |
Oripavine is an opioid and the major metabolite of thebaine. It is the precursor to the semi-synthetic compounds etorphine and buprenorphine. Although this chemical compound has analgesic potency comparable to morphine, it is not used clinically due to severe adverse effects and a low therapeutic index. Being a precursor to a series of extremely strong opioids, oripavine is a controlled substance in some jurisdictions.